Active Filter(s):
Details:
Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Lead Product(s): Safinamide Mesylate
Therapeutic Area: Neurology Product Name: Xadago
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Newron Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 12, 2021